Background

Digital therapeutics (DTx) and smart devices represent one of the most quickly growing and evolving areas within the digital health world. Given the expedited R&D time to bring a new digital therapies to market, coupled with strong interest from consumers and professionals to adopt these technologies, the DTx space is poised for rapid growth. For professionals in the pharmaceutical space it is becoming more important than ever to track the innovations, developments, and the emerging technologies, brands and key players in the DTx world, and to understand the opportunities for partnerships between pharma and tech companies.

Solution Summary

To help pharmaceutical professionals stay abreast of ongoing developments in the DTx space, DRG is conducting a comprehensive research program to provide regular updates and analysis. This Digital Therapeutics and Smart Device Landscape Tracking Study will be released every other month on a subscription basis. The project begins with DRGs foundational clinical, therapy area, and customer expertise and layers in research gathered from search and social media analytics, integration of proprietary datasets, desk research, and survey-based customer insights to provide contextualization. The outcomes of the study will track the market to understand trends, identify prominent players and emerging disruptors, and provide a deeper profiling of tech companies in the space including their business models and the opportunities they represent for pharma.

Key questions answered through the Digital Therapeutics and Smart Device Landscape Tracker include:

  • Who are the established players in the digital therapeutics space, and who are tech startups to watch?
  • What are the emerging digital therapies coming to market, and what disease areas do they address?
  • What partnerships are forming between pharma manufacturers and tech companies to support DTx development?
  • What opportunities exist for pharma companies to capitalize on these innovations?
  • What are the market perceptions towards these emerging therapies and companies?